Exploring CIP2A modulators using multiple molecular modeling approaches.

Area of Science:

• Oncology
• Structural Biology
• Drug Discovery

Background:

• Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncoprotein that promotes cancer by interacting with proteins like MYC and Protein Phosphatase 2A (PP2A).
• CIP2A inhibits PP2A, particularly MYC-associated PP2A, to enhance MYC stability and function, contributing to cancer development.
• The availability of CIP2A's crystal structure has opened avenues for developing targeted therapeutics.

Purpose of the Study:

• To identify modulators of the CIP2A homo-dimer using structure-based drug design approaches.
• To screen a large compound library for potential CIP2A inhibitors.
• To validate the binding stability and interactions of identified hit compounds.

Main Methods:

• Virtual screening of the Maybridge Screening Collection database (approx. 62,000 compounds).
• Identification of hotspot regions on the CIP2A protein-protein interaction interface using HotPoint, SiteMap, and icmPocketFinder.
• Molecular docking, molecular dynamics simulations, ADME profiling, MM-PBSA binding free energy calculations, and Density Functional Theory (DFT) for hit compound analysis.

Main Results:

• A multi-step virtual screening approach identified potent modulators of CIP2A.
• Hit compounds demonstrated significant molecular interactions within the homo-dimer interface hotspot region, ensuring binding stability.
• Calculated average binding free energy (ΔG) values ranged from -3.4 x 10^-2 to -1.1 x 10^-2 KJ/mol, indicating promising CIP2A modulation.

Conclusions:

• The study successfully identified promising CIP2A modulators using advanced structure-based drug design.
• These identified compounds show potential for further development as targeted cancer therapeutics.
• The findings highlight the utility of computational approaches in discovering novel drug candidates for oncoproteins.